1. Catalog
  2. Nodes
  3. p(HGNC:PICALM)

p(HGNC:PICALM)

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
PICALM
Namespace
hgnc
Namespace Version
20180906
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns

Appears in Networks 4

Clearance systems in the brain-implications for Alzheimer disease. v1.0.1

Clearance of Amyloid Beta and Tau in Alzheimer’s Disease:from Mechanisms to Therapy v1.0.1

Tau Biochemistry v1.2.5

Tau Biochemistry Section of NESTOR

Alzheimer’s disease and the autophagic-lysosomal system v1.0.0

In-Edges 8

path(MESH:"Alzheimer Disease") association p(HGNC:PICALM) View Subject | View Object

although genome-wide association studies have linked LOAD to several other genetic variants, such as TREM2 (triggering receptor expressed on myeloid cells 2),27 clusterin (CLU),28 and phosphatidylinositol-binding clathrin assembly protein (PICALM).28,29 PubMed:26195256

Appears in Networks:

path(MESH:"Alzheimer Disease") negativeCorrelation p(HGNC:PICALM) View Subject | View Object

And in AD, the decreasing expression of PICALM in brain endothelium reduces Aβ clearance (Zhao et al. 2015b) PubMed:29626319

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

p(HGNC:BECN1) positiveCorrelation p(HGNC:PICALM) View Subject | View Object

A highly significant correlation was found between decreased levels of PICALM and increased levels of LC3-II (p=0.0032) or decreased levels of Beclin-1 (p=0.0295) in the total brain lysates from these diseases (Fig 6D,E). PubMed:27260836

Appears in Networks:
Annotations
Disease Ontology (DO)
Alzheimer's disease
Disease Ontology (DO)
Down syndrome
Disease Ontology (DO)
Pick's disease
Disease Ontology (DO)
progressive supranuclear palsy

p(HGNC:MAP1LC3B) negativeCorrelation p(HGNC:PICALM) View Subject | View Object

A highly significant correlation was found between decreased levels of PICALM and increased levels of LC3-II (p=0.0032) or decreased levels of Beclin-1 (p=0.0295) in the total brain lysates from these diseases (Fig 6D,E). PubMed:27260836

Appears in Networks:
Annotations
Disease Ontology (DO)
Alzheimer's disease
Disease Ontology (DO)
Down syndrome
Disease Ontology (DO)
Pick's disease
Disease Ontology (DO)
progressive supranuclear palsy

p(HGNC:MAPT, pmod(Ph)) association p(HGNC:PICALM) View Subject | View Object

Phosphatidylinositol binding clathrin assembly protein, PICALM (aka CALM) assembles adaptor protein-2 (AP-2) to clathrin, thus participating in clathrin-mediated endocytosis. We have previously reported that the level of full-length PICALM is decreased in AD brains; PICALM was co-localised with phosphorylated tau in NFTs and in granulovacuolar degenerations (GVDs) in the brains of AD patients and of individuals with Down syndrome but was not observed in amyloid plaques (Ando et al., 2013). PubMed:27260836

Appears in Networks:
Annotations
Disease Ontology (DO)
Alzheimer's disease
Disease Ontology (DO)
Down syndrome

p(HGNC:MAPT, pmod(Ph)) association p(HGNC:PICALM) View Subject | View Object

In PSP cases, both coiled bodies (Fig. 2 D-F) and NFTs (Fig. 2G-I) in the striatum showed a complete co-localisation of PICALM and phosphotau immunoreactivies. PubMed:27260836

Appears in Networks:
Annotations
Uberon
striatum
Disease Ontology (DO)
progressive supranuclear palsy

path(MESH:"Alzheimer Disease") negativeCorrelation p(HGNC:PICALM) View Subject | View Object

Phosphatidylinositol binding clathrin assembly protein, PICALM (aka CALM) assembles adaptor protein-2 (AP-2) to clathrin, thus participating in clathrin-mediated endocytosis. We have previously reported that the level of full-length PICALM is decreased in AD brains; PICALM was co-localised with phosphorylated tau in NFTs and in granulovacuolar degenerations (GVDs) in the brains of AD patients and of individuals with Down syndrome but was not observed in amyloid plaques (Ando et al., 2013). PubMed:27260836

Appears in Networks:
Annotations
Disease Ontology (DO)
Alzheimer's disease
Disease Ontology (DO)
Down syndrome

a(CHEBI:"amyloid-beta") positiveCorrelation p(HGNC:PICALM) View Subject | View Object

Overexpression of PICALM in APP/PS1 mice substantially elevates Aβ levels, whereas knockdown reduces the Aβ plaque load, respectively [98] PubMed:29758300

Appears in Networks:

Out-Edges 24

p(HGNC:PICALM) association path(MESH:"Alzheimer Disease") View Subject | View Object

although genome-wide association studies have linked LOAD to several other genetic variants, such as TREM2 (triggering receptor expressed on myeloid cells 2),27 clusterin (CLU),28 and phosphatidylinositol-binding clathrin assembly protein (PICALM).28,29 PubMed:26195256

Appears in Networks:

p(HGNC:PICALM) increases tloc(a(CHEBI:"amyloid-beta"), fromLoc(MESH:"Blood-Brain Barrier"), toLoc(MESH:Blood)) View Subject | View Object

PICALM, mainly expressed in endothelial cells of vascular walls, contributes to the transport of Aβ across the BBB into blood (Xu et al. 2015) PubMed:29626319

Appears in Networks:

p(HGNC:PICALM) decreases a(CHEBI:"amyloid-beta") View Subject | View Object

And in AD, the decreasing expression of PICALM in brain endothelium reduces Aβ clearance (Zhao et al. 2015b) PubMed:29626319

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

p(HGNC:PICALM) negativeCorrelation path(MESH:"Alzheimer Disease") View Subject | View Object

And in AD, the decreasing expression of PICALM in brain endothelium reduces Aβ clearance (Zhao et al. 2015b) PubMed:29626319

Appears in Networks:
Annotations
MeSH
Alzheimer Disease

p(HGNC:PICALM) increases complex(p(HBP:"AP-2 complex"), p(HGNCGENEFAMILY:"Clathrin subunits")) View Subject | View Object

Phosphatidylinositol binding clathrin assembly protein, PICALM (aka CALM) assembles adaptor protein-2 (AP-2) to clathrin, thus participating in clathrin-mediated endocytosis. We have previously reported that the level of full-length PICALM is decreased in AD brains; PICALM was co-localised with phosphorylated tau in NFTs and in granulovacuolar degenerations (GVDs) in the brains of AD patients and of individuals with Down syndrome but was not observed in amyloid plaques (Ando et al., 2013). PubMed:27260836

Appears in Networks:

p(HGNC:PICALM) negativeCorrelation path(MESH:"Alzheimer Disease") View Subject | View Object

Phosphatidylinositol binding clathrin assembly protein, PICALM (aka CALM) assembles adaptor protein-2 (AP-2) to clathrin, thus participating in clathrin-mediated endocytosis. We have previously reported that the level of full-length PICALM is decreased in AD brains; PICALM was co-localised with phosphorylated tau in NFTs and in granulovacuolar degenerations (GVDs) in the brains of AD patients and of individuals with Down syndrome but was not observed in amyloid plaques (Ando et al., 2013). PubMed:27260836

Appears in Networks:
Annotations
Disease Ontology (DO)
Alzheimer's disease
Disease Ontology (DO)
Down syndrome

p(HGNC:PICALM) partOf complex(GO:"neurofibrillary tangle") View Subject | View Object

Appears in Networks:

p(HGNC:PICALM) partOf complex(GO:"neurofibrillary tangle") View Subject | View Object

Appears in Networks:

p(HGNC:PICALM) association p(HGNC:MAPT, pmod(Ph)) View Subject | View Object

Phosphatidylinositol binding clathrin assembly protein, PICALM (aka CALM) assembles adaptor protein-2 (AP-2) to clathrin, thus participating in clathrin-mediated endocytosis. We have previously reported that the level of full-length PICALM is decreased in AD brains; PICALM was co-localised with phosphorylated tau in NFTs and in granulovacuolar degenerations (GVDs) in the brains of AD patients and of individuals with Down syndrome but was not observed in amyloid plaques (Ando et al., 2013). PubMed:27260836

Appears in Networks:
Annotations
Disease Ontology (DO)
Alzheimer's disease
Disease Ontology (DO)
Down syndrome

p(HGNC:PICALM) association p(HGNC:MAPT, pmod(Ph)) View Subject | View Object

In PSP cases, both coiled bodies (Fig. 2 D-F) and NFTs (Fig. 2G-I) in the striatum showed a complete co-localisation of PICALM and phosphotau immunoreactivies. PubMed:27260836

Appears in Networks:
Annotations
Uberon
striatum
Disease Ontology (DO)
progressive supranuclear palsy

p(HGNC:PICALM) partOf a(HBP:"granulovacuolar degeneration") View Subject | View Object

Appears in Networks:

p(HGNC:PICALM) partOf complex(GO:"Pick body") View Subject | View Object

Appears in Networks:

p(HGNC:PICALM) partOf complex(GO:"Cajal body") View Subject | View Object

Appears in Networks:

p(HGNC:PICALM) negativeCorrelation p(HGNC:MAP1LC3B) View Subject | View Object

A highly significant correlation was found between decreased levels of PICALM and increased levels of LC3-II (p=0.0032) or decreased levels of Beclin-1 (p=0.0295) in the total brain lysates from these diseases (Fig 6D,E). PubMed:27260836

Appears in Networks:
Annotations
Disease Ontology (DO)
Alzheimer's disease
Disease Ontology (DO)
Down syndrome
Disease Ontology (DO)
Pick's disease
Disease Ontology (DO)
progressive supranuclear palsy

p(HGNC:PICALM) positiveCorrelation p(HGNC:BECN1) View Subject | View Object

A highly significant correlation was found between decreased levels of PICALM and increased levels of LC3-II (p=0.0032) or decreased levels of Beclin-1 (p=0.0295) in the total brain lysates from these diseases (Fig 6D,E). PubMed:27260836

Appears in Networks:
Annotations
Disease Ontology (DO)
Alzheimer's disease
Disease Ontology (DO)
Down syndrome
Disease Ontology (DO)
Pick's disease
Disease Ontology (DO)
progressive supranuclear palsy

p(HGNC:PICALM) hasVariant p(HGNC:PICALM, var("?")) View Subject | View Object

Appears in Networks:

p(HGNC:PICALM) positiveCorrelation a(CHEBI:"amyloid-beta") View Subject | View Object

Overexpression of PICALM in APP/PS1 mice substantially elevates Aβ levels, whereas knockdown reduces the Aβ plaque load, respectively [98] PubMed:29758300

Appears in Networks:

p(HGNC:PICALM) increases a(CHEBI:"amyloid-beta") View Subject | View Object

A recent line of work revealed Aβ-promoting function of PICALM by demonstrating that PICALM depletion decreased Aβ generation through disrupting clathrin-mediated endocytosis and internalization of γ-secretase [99,100]. PubMed:29758300

Appears in Networks:

p(HGNC:PICALM) increases tloc(a(CHEBI:"amyloid-beta"), fromLoc(MESH:"Endothelial Cells"), toLoc(MESH:Blood)) View Subject | View Object

PICALM may also promote amyloid clearance from the brain by internalizing Aβ into endothelial cells and ultimately into to the bloodstream [101] PubMed:29758300

Appears in Networks:

p(HGNC:PICALM) increases path(MESH:"Plaque, Amyloid") View Subject | View Object

Overexpression of PICALM in APP/PS1 mice substantially elevates Aβ levels, whereas knockdown reduces the Aβ plaque load, respectively [98] PubMed:29758300

Appears in Networks:

p(HGNC:PICALM) increases bp(GO:"clathrin-dependent endocytosis") View Subject | View Object

A recent line of work revealed Aβ-promoting function of PICALM by demonstrating that PICALM depletion decreased Aβ generation through disrupting clathrin-mediated endocytosis and internalization of γ-secretase [99,100]. PubMed:29758300

Appears in Networks:

p(HGNC:PICALM) increases tloc(complex(GO:"gamma-secretase complex"), fromLoc(GO:"extracellular space"), toLoc(GO:intracellular)) View Subject | View Object

A recent line of work revealed Aβ-promoting function of PICALM by demonstrating that PICALM depletion decreased Aβ generation through disrupting clathrin-mediated endocytosis and internalization of γ-secretase [99,100]. PubMed:29758300

Appears in Networks:

p(HGNC:PICALM) regulates bp(GO:macroautophagy) View Subject | View Object

However, recent work provides direct evidence that PICALM can also modulate macroautophagy, via its role in SNARE endocytosis to clear tau aggregates [102]. PubMed:29758300

Appears in Networks:

p(HGNC:PICALM) increases tloc(complex(GO:"SNARE complex"), fromLoc(GO:"extracellular space"), toLoc(GO:intracellular)) View Subject | View Object

However, recent work provides direct evidence that PICALM can also modulate macroautophagy, via its role in SNARE endocytosis to clear tau aggregates [102]. PubMed:29758300

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.